These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 16239637)

  • 1. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Nissen SE; Wolski K; Topol EJ
    JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selling safety--lessons from muraglitazar.
    Brophy JM
    JAMA; 2005 Nov; 294(20):2633-5. PubMed ID: 16239638
    [No Abstract]   [Full Text] [Related]  

  • 4. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
    Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events related to muraglitazar use in diabetes.
    Najman DM
    JAMA; 2006 May; 295(17):1997; author reply 1998. PubMed ID: 16670404
    [No Abstract]   [Full Text] [Related]  

  • 6. Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
    Rubin CJ; De Pril V; Fiedorek FT
    Diab Vasc Dis Res; 2009 Apr; 6(2):120-32. PubMed ID: 20368202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events related to muraglitazar use in diabetes.
    Parra D; Beckey C; Thomas T
    JAMA; 2006 May; 295(17):1997-8; author reply 1998. PubMed ID: 16670403
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
    Rubin CJ; Viraswami-Appanna K; Fiedorek FT
    Diab Vasc Dis Res; 2009 Jul; 6(3):205-15. PubMed ID: 20368213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jun; 7(9):1229-33. PubMed ID: 16732709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
    Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
    Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
    Rubin CJ; Ledeine JM; Fiedorek FT
    Diab Vasc Dis Res; 2008 Sep; 5(3):168-76. PubMed ID: 18777489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muraglitazar (Bristol-Myers Squibb/Merck).
    Barlocco D
    Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
    Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
    JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.